Watch Black Diamond Therapeutics Inc for free: we tell you when fair value or trend changes.

Black Diamond Therapeutics Inc (BDTX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Black Diamond Therapeutics Inc stock $5.13, price $1.74, upside +195.7%, quality 81 out of 100. Rating: strongly undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

23 models, one by oneBear $4.01 to bull $6.21 Growth analysisrevenue history, year by year Quality 81/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Thin data Nov 8, 2026

Black Diamond Therapeutics Inc

BDTX · US

Undervalued, but in a downtrend

The stock costs 66% less than our calculation considers fair.

Fair value $5.13 · Strongly undervalued

Quality 81/100

Highly profitable · 32.0% net margin (FY2025)

Ranks above peers (8/9)

Positive coverage

Even on cautious assumptions the value is 131% above the price ($4.01).

Moderate moat 61/100 · thin data

Weak Growth

Negative free cash flow over the last twelve months

Thin data

Watch Black Diamond Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $1.25 – $10.38 · fair‑value band $4.01 – $6.21 · the $1.74 price screens below the $5.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Black Diamond Therapeutics in your weekly email

Every Wednesday you see whether Black Diamond Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.

Show moreShow less

The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.

In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.

Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Black Diamond Therapeutics Inc (BDTX) currently trades at $1.74, while our model-based Fair Value estimate is $5.13, implying the stock looks roughly 66% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $7.20 per share, and 23 of the 23 models we run sit above the $1.74 price.

Bear case: the Asset-Based group reads lowest at $1.77, and 0 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: $4.01 (bear) to $6.21 (bull), the price of $1.74 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 81/100 (high quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Black Diamond Therapeutics Inc reported revenue of $70.0M in FY2025 versus $0 in FY2021. Reported net income was $22.4M in FY2025.

Key figures

Market cap $99.5M Micro · EPS (TTM) $−0.7500 · Net margin 32.0% · Return on equity −37.2% · Return on assets (EBIT) −43.1% (5-year average) · Free cash flow $29.6M · Net cash $2.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 196%, BDTX screens cheaper than that median.

Fair Value models

Bear $4.01 Fair Value $5.13 Bull $6.21

Price $1.74 · Upside +195.7%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

EPV $2.23 $2.42 $2.56 70

FCF DCF $4.21 $5.25 $6.40 69

Growth DCF $4.21 $5.13 $6.09 67

All 23 models by family

DCF Models

FCF DCF $4.21 $5.25 $6.40 69

5Y Revenue Exit $3.49 $4.63 $5.99 62

5Y EBITDA Exit $3.90 $5.37 $7.00 63

5Y P/E Exit $5.08 $7.51 $9.95 59

10Y Revenue Exit $3.77 $4.71 $5.83 57

10Y EBITDA Exit $4.01 $5.10 $6.39 58

10Y P/E Exit $4.58 $6.20 $8.05 54

Earnings-Based

Graham-Dodd $2.65 $7.06 $9.23 51

Lynch FV $1.37 $1.95 $2.54 48

PEG = 1.0 $1.37 $1.95 $2.54 45

EPV $2.23 $2.42 $2.56 70

Multiples

P/E Multiple $6.44 $8.59 $10.73 63

P/S Multiple $3.21 $4.28 $5.34 58

P/B Multiple $1.69 $2.26 $2.82 55

EV/EBIT $4.46 $5.93 $7.41 63

EV/EBITDA $3.74 $4.97 $6.21 64

EV/Revenue $2.60 $3.70 $4.80 51

Asset-Based

NCAV (Graham) $1.17 $1.77 $2.22 52

Growth DCF

Growth DCF $4.21 $5.13 $6.09 67

Rev-Margin DCF $3.49 $4.71 $6.07 62

Economic Profit

Residual Income $1.85 $2.20 $2.83 61

ROIC Compounder $2.26 $2.51 $2.75 61

Growth Earnings

Growth-Adj P/E $5.04 $7.20 $9.36 59

Open the full fair value analysis →

Quality Score breakdown

Overall quality 81/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 76

How much profit the company makes from its sales and capital

Quality Growth 100

Are margins and returns getting better?

Cashflow 89

Do the profits arrive as real cash?

Financial strength 70

Debt, balance sheet and risk of trouble

Investment 100

Does it invest with discipline instead of growing at any price?

Low Volatility 0

How calm the share price moves, does not count

Price momentum 12

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 2

Distance to the 52-week high, does not count

New shares 42

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100

Revenue growth is weak, negative or inconsistent.

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year

not computed

Growth Forecast

Little optimism in the price

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

less than -40 %

The company could shrink this much every year for the next five years and today's price would still be justified.

What forecasts expect

n/a

No analyst forecast available.

Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.

Watch BDTX, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (78 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue? Yahoo Finance · Sep 4, 2026
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst Yahoo Finance · May 27, 2026
Black Diamond Stock Outlook After Q1 Beat and Cash Runway Yahoo Finance · May 27, 2026
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know Yahoo Finance · May 27, 2026

Compare Black Diamond Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 8/8 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 81 · Top 25%

Fair Value upside +195.7% · Top 25%

Profitability

Return on assets 15.6% · Top 25%

Net margin (12 months) 32.0% · Top 25%

Operating margin (12 months) 0.0% · Above median

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.89× · Cheapest 25%

Price / free cash flow (fiscal year) 3.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Incyte Corporation INCY	$119.65	$199.23	+67%	vs BDTX
Regeneron Pharmaceuticals, Inc REGN	$904.35	$1,275	+41%	vs BDTX
Genmab A/S GMAB	kr 3,527	kr 3,999	+13%	vs BDTX
Samsung Biologics Co 207940	1,516,000 KRW	1,667,600 KRW	+10%	vs BDTX
WuXi Biologics (Cayman) Inc 2269	HK$47.62	HK$52.38	+10%	vs BDTX
Vertex Pharmaceuticals Incorporated VRTX	$547.09	$596.75	+9%	vs BDTX
argenx SE ARGX	$927.21	$908.40	−2%	vs BDTX
CSL Limited CSL	A$200.77	A$183.04	−9%	vs BDTX
Celltrion, Inc 068270	211,000 KRW	74,945 KRW	−64%	vs BDTX
Royalty Pharma plc RPRX	$67.30	$19.01	−72%	vs BDTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Black Diamond Therapeutics Inc: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/BDTX?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/BDTX.US.svg" width="360" height="84" alt="Black Diamond Therapeutics Inc: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Black Diamond Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/BDTX

Frequently asked questions

Is Black Diamond Therapeutics Inc (BDTX) overvalued or undervalued?

As of Nov 8, 2026, our model estimates a fair value of $5.13 versus a price of $1.74, about +196% upside (undervalued).

What is the fair value of BDTX?

Our model-based fair value for Black Diamond Therapeutics Inc is $5.13 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.74.

What is the quality score of BDTX?

Black Diamond Therapeutics Inc has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Black Diamond Therapeutics Inc (BDTX)?

Our model-based price target is the fair value of $5.13 (as of Nov 8, 2026) from 23 valuation models. Cautious scenario $4.01, optimistic scenario $6.21. It is a calculation from audited fundamentals, not an analyst target.

What is the Black Diamond Therapeutics Inc stock forecast for 2026?

Our models put fair value at $5.13, about +196% upside versus a price of $1.74 (undervalued). Cautious scenario $4.01, optimistic scenario $6.21. The calculation is refreshed regularly with new filings.

What growth is priced into Black Diamond Therapeutics Inc (BDTX)?

For today's price to be fair in a discounted-cash-flow model, Black Diamond Therapeutics Inc would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.

What discount rate (WACC) does the fair value of BDTX use?

Our models discount Black Diamond Therapeutics Inc at 15.2 %: a base by market capitalisation (micro), damped by beta 3.46, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Black Diamond Therapeutics Inc that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.2 %) and the same formula as our fair value.

How fast is the sector of Black Diamond Therapeutics Inc (BDTX) growing?

The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Black Diamond Therapeutics Inc (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Black Diamond Therapeutics Inc (BDTX)?

The free-cash-flow yield on the price is 29.75 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Black Diamond Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Black Diamond Therapeutics Inc (BDTX)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Black Diamond Therapeutics Inc it is $5.13 per share (as of Nov 8, 2026), against a price of $1.74. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).

Is Black Diamond Therapeutics Inc stock overvalued or undervalued in 2026?

As of Nov 8, 2026, BDTX trades below its calculated fair value: price $1.74, fair value $5.13, a gap of about +196% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BDTX?

No. The price is what the market pays today ($1.74); the fair value is what the company's own numbers justify ($5.13). For Black Diamond Therapeutics Inc the two are $3.40 per share apart. That gap is exactly why we show both numbers side by side.

How much is Black Diamond Therapeutics Inc worth?

The market values Black Diamond Therapeutics Inc at about $99.5M (market capitalisation, as of Nov 8, 2026). Per share that is $1.74; our models calculate a fair value of $5.13 per share.

What do the bullish and bearish scenarios say about BDTX?

Our models span a range for Black Diamond Therapeutics Inc: cautious scenario $4.01, base $5.13, optimistic $6.21 per share (as of Nov 8, 2026, price $1.74). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Black Diamond Therapeutics Inc (BDTX)?

Balance-sheet figures for Black Diamond Therapeutics Inc (as of Nov 8, 2026): return on equity −37.2%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.

How far is BDTX from its 52-week high?

Black Diamond Therapeutics Inc trades at $1.74, about 64% below its 52-week high of $4.87 and 8% above the low of $1.61 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.13 is for.

Which stocks are comparable to Black Diamond Therapeutics Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Black Diamond Therapeutics Inc stock attractive at the current price?

The data as of Nov 8, 2026: price $1.74, calculated fair value $5.13 (+196%), Quality Score 81/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BDTX calculated?

We run Black Diamond Therapeutics Inc through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $5.13 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. Black Diamond Therapeutics Inc currently trades 66% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Black Diamond Therapeutics Inc (BDTX)?

The closing price on Nov 6, 2026 was $1.74. Our model-based fair value is $5.13, about +196% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Black Diamond Therapeutics Inc right now?

The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($4.01). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Black Diamond Therapeutics Inc

How large is the market capitalisation of Black Diamond Therapeutics Inc (BDTX)?

The market capitalisation of Black Diamond Therapeutics Inc is $99.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Black Diamond Therapeutics Inc (BDTX)?

Earnings per share at Black Diamond Therapeutics Inc are $−0.7500. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Black Diamond Therapeutics Inc (BDTX)?

The net margin of Black Diamond Therapeutics Inc is 32.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Black Diamond Therapeutics Inc (BDTX)?

The return on equity (ROE) of Black Diamond Therapeutics Inc is −37.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Black Diamond Therapeutics Inc (BDTX)?

On an EBIT basis the return on assets of Black Diamond Therapeutics Inc is −43.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much net cash does Black Diamond Therapeutics Inc (BDTX) hold?

Black Diamond Therapeutics Inc holds more cash than debt, $2.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Black Diamond Therapeutics Inc in the live analysis

One click puts Black Diamond Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.